Biocompatibility of implantable synthetic polymeric drug carriers: Focus on brain biocompatibility

Biomaterials

Volumn 24, Issue 19, 2003, Pages 3311-3331

  Fournier, E ^a,b   Passirani, C ^a   Montero Menei, C N ^a   Benoit, J P ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Biocompatibility; Brain; Drug delivery; Immune response; Inflammatory response; Synthetic polymer

Indexed keywords

BIOCOMPATIBILITY; DISEASES; DRUG THERAPY; IMMUNOLOGY; TISSUE;

SYNTHETIC POLYMERIC DRUG CARRIERS;

ORGANIC POLYMERS;

ALGINIC ACID; BIOMATERIAL; BRAIN PROTEIN; CHITOSAN; COLLAGEN; DENDRIMER; DEXTRAN; DRUG CARRIER; GELATIN; HYALURONIC ACID; NANOPARTICLE; POLYHYDROXYALKANOIC ACID; POLYMER; STARCH;

ADSORPTION; BIOCOMPATIBILITY; BRAIN NERVE CELL; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; DEVICE; DRUG FORMULATION; FOREIGN BODY REACTION; IMMUNOLOGY; IMPLANTATION; IN VIVO STUDY; LYMPHATIC DRAINAGE; MICELLE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0037619257     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(03)00161-3     Document Type: Review

References (150)

1. Laurencin C.T., Elgendy H. The biocompatibility and toxicity of degradable polymeric materials. implications for drug delivery Domb A.J. Polymeric site-specific pharmacotherapy. 1994;27-46 John Wiley & Sons Ltd, New York.
2. Castner D.G., Ratner B.D. Biomedical surface science. foundations to frontiers Surf Sci. 500:2002;28-60.
3. Anderson J.M., Langone J.J. Issues and perspectives on the biocompatibility and immunotoxicity evaluation of implanted controlled release systems. J Controlled Release. 57:1999;107-113.
4. Ratner B.D. Reducing capsular thickness and enhancing angiogenesis around implant drug release systems. J Controlled Release. 78:2002;211-218.
5. Williams D.F. The Williams dictionary of biomaterials. 1999;University Press, Liverpool.
6. Williams D.F. Definitions in biomaterials. Williams D.F. Progress in biomedical engineering. 1987;Elsevier, Amsterdam.
7. Gentile F.T., Doherty E.J., Rein D.H., Shoichet M.S., Winn S.R. Polymer science for macroencapsulation of cells for central nervous system transplantation. React Polym. 25:1995;207-227.
8. Sieminski A.L., Gooch K.J. Biomaterial-microvasculature interactions. Biomaterials. 21:2000;2233-2241.
9. Rihova B. Immunocompatibility and biocompatibility of cell delivery systems. Adv Drug Delivery Rev. 42:2000;65-80.
10. Babensee J.E., Anderson J.M., McIntire L.V., Mikos A.G. Host response to tissue engineered devices. Adv Drug Delivery Rev. 33:1998;111-139.
11. Williams D.F. Tissue-biomaterial interactions. J Mater Sci. 22:1987;3421-3445.
12. Rihova B. Biocompatibility of biomaterials. hemocompatibility, immunocompatibility and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers Adv Drug Delivery Rev. 21:1996;157-176.
13. Bjorklund A., Lindvall O. Cell replacement therapies for central nervous system disorders. Nat Neurosci. 3:2000;537-544.
14. Gutman R.L., Peacock G., Lu D.R. Targeted drug delivery for brain cancer treatment. J Controlled Release. 65:2000;31-41.
15. Menei P., Croue A., Daniel V., Pouplard-Barthelaix A., Benoit J.P. Fate and biocompatibility of three types of microspheres implanted into the brain. J Biomed Mater Res. 28:1994;1079-1085.
16. Uchegbu I.F., Schatzlein A.G., Tetley L., Gray A.I., Sludden J., Siddique S., Mosha E. Polymeric chitosan-based vesicles for drug delivery. J Pharm Pharmacol. 50:1998;453-458.
17. Kumar M.N.V.R. A review of chitin and chitosan applications. Reactive Funct Polym. 46:2000;1-27.
18. Borchard G. Modern drug delivery applications of chitosan. Adv Drug Delivery Rev. 52:2001;103.
19. Cadee J.A., Brouwer L.A., den Otter W., Hennink W.E., van Luyn M.J. A comparative biocompatibility study of microspheres based on crosslinked dextran or poly(lactic-co-glycolic) acid after subcutaneous injection in rats. J Biomed Mater Res. 56:2001;600-609.
20. Draye J.P., Delaey B., Van de Voorde A., Van Den Bulcke A., De Reu B., Schacht E. In vitro and in vivo biocompatibility of dextran dialdehyde cross-linked gelatin hydrogel films. Biomaterials. 19:1998;1677-1687.
21. Pouton C.W., Akhtar S. Biosynthetic polyhydroxyalkanoates and their potential in drug delivery. Adv Drug Delivery Rev. 18:1996;133-162.
22. Zinn M., Witholt B., Egli T. Occurrence, synthesis and medical application of bacterial polyhydroxyalkanoate. Adv Drug Delivery Rev. 53:2001;5-21.
23. Yang X., Zhao K., Chen G.Q. Effect of surface treatment on the biocompatibility of microbial polyhydroxyalkanoates. Biomaterials. 23:2002;1391-1397.
24. Fujioka K., Maeda M., Hojo T., Sano A. Protein release from collagen matrices. Adv Drug Delivery Rev. 31:1998;247-266.
25. Geiger M., Friess W. Collagen sponge implants - applications, characteristics and evaluation. Part I Pharm Technol Eur. 14:2002;48-56.
26. De Vos P., Hoogmoed C.G., Busscher H.J. Chemistry and biocompatibility of alginate-PLL capsules for immunoprotection of mammalian cells. J Biomed Mater Res. 60:2002;252-259.
27. Cortesi R., Nastruzzi C., Davis S.S. Sugar cross-linked gelatin for controlled release. microspheres and disks Biomaterials. 19:1998;1641-1649.
28. Vandelli M.A., Rivasi F., Guerra P., Forni F., Arletti R. Gelatin microspheres crosslinked with D,L-glyceraldehyde as a potential drug delivery system. preparation, characterisation, in vitro and in vivo studies Int J Pharm. 215:2001;175-184.
29. Vercruysse K.P., Prestwich G.D. Hyaluronate derivatives in drug delivery. Crit Rev Ther Drug Carrier Syst. 15:1998;513-555.
30. ® implantation: host response and delivery of a potent analog of the growth hormone-releasing factor. Int J Pharm. 232:2002;119-129.
31. Marques A.P., Reis R.L., Hunt J.A. The biocompatibility of novel starch-based polymers and composites. in vitro studies Biomaterials. 23:2002;1471-1478.
32. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Delivery Rev. 47:2001;65-81.
33. Sefton M.V., Sawyer A., Gorbet M., Black J.P., Cheng E., Gemmell C., Pottinger-Cooper E. Does surface chemistry affect thrombogenicity of surface modified polymers? J Biomed Mater Res. 55:2001;447-459.
34. Yang L., Alexandridis P. Physicochemical aspects of drug delivery and release from polymer-based colloids. Curr Opin Colloid Interf Sci. 5:2000;132-143.
35. Kakisawa Y., Kataoka K. Block copolymer micelles for delivery of gene and related compounds. Adv Drug Delivery Rev. 54:2002;203-222.
36. Lavasanifar A., Samuel J., Kwon G.S. Poly(ethylene oxide)-block-poly(L-amino acid) micelles drug delivery. Adv Drug Delivery Rev. 2002:2002;169-190.
37. 125I-labelled polyamidoamine dendrimers in vivo J Controlled Release. 65:2000;133-148.
38. Lim Y.B., Han S.O., Kong H.U., Lee Y., Park J.S., Jeong B., Kim S.W. Biodegradable polyester, poly[alpha-(4-aminobutyl)-L-glycolic acid], as a non-toxic gene carrier. Pharm Res. 17:2000;811-816.
39. Pedone E., Cavallaro G., Richardson S.C., Duncan R., Giammona G. Alpha,beta-poly(asparthylhydrazide)-glycidyltrimethylammonium chloride copolymers (PAHy-GTA). novel polymers with potential for DNA delivery J Controlled Release. 77:2001;139-153.
40. Baumann H., Gauldie J. The acute phase response. Immunol Today. 15:1994;74-80.
41. Tang L., Eaton J.W. Inflammatory responses to biomaterials. Am J Clin Pathol. 103:1995;466-471.
42. Anderson J.M., Shive M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Delivery Rev. 28:1997;5-24.
43. Tang L. Mechanisms of fibrinogen domains. biomaterial interactions J Biomater Sci Polym Edition. 9:1998;1257-1266.
44. Remes A., Williams D.F. Immune response in biocompatibility. Biomaterials. 13:1992;731-743.
45. Babensee J.E., Sefton M.V. Protein delivery by microencapsulated cells. Park K. Controlled drug delivery, challenges and strategies. 1997;311-332 American Chemical Society, Washington, DC.
46. Babensee J.E., Sefton M.V. Viability of HEMA-MMA microencapsulated model hepatoma cells in rats and the host response. Tissue Eng. 6:2000;165-182.
47. Kissel T., Li Y., Unger F. ABA-triblock copolymers from biodegradable polyester A-blocks and hydrophilic poly(ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins. Adv Drug Delivery Rev. 54:2002;99-134.
48. Xiao B.G., Link H. Immune regulation within the central nervous system. J Neurol Sci. 157:1998;1-12.
49. Pryce G., Male D., Campbell I., Greenwood J. Factors controlling T-cell migration across rat cerebral endothelium in vitro. J Neuroimmunol. 75:1997;84-94.
50. Hickey W.F. Basic principles of immunological surveillance of the normal central nervous system. Glia. 36:2001;118-124.
51. Gloor S.M., Wachtel M., Bolliger M.F., Ishihara H., Landmann R., Frei K. Molecular and cellular permeability control at the blood-brain barrier. Brain Res. 36:2001;258-264.
52. Prat A., Biernacki K., Wosik K., Antel J.P. Glial cell influence on the human blood-brain barrier. Glia. 36:2001;145-155.
53. Perry V.H. A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. J Neuroimmunol. 90:1998;113-121.
54. Weller R.O., Engelhardt B., Phillips M.J. Lymphocyte targeting of the central nervous system. a review of afferent and efferent CNS-immune pathways Brain Pathol. 6:1996;275-288.
55. Barron K.D. The microglial cell. A historical review. J Neurol Sci. 134:1995;57-68.
56. Aloisi F., Ria F., Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells. different roles for microglia and astrocytes Immunol Today. 21:2000;141-147.
57. Becher B., Prat A., Antel J.P. Brain-immune connection. immuno-regulatory properties of CNS-resident cells Glia. 29:2000;293-304.
58. Nakajima K., Kohsaka S. Microglia. activation and their significance in the central nervous system J Biochem. 130:2001;169-175.
59. Norenberg M.D. Astrocyte responses to CNS injury. J Neuropathol Exp Neurol. 53:1994;213-220.
60. Dong Y., Benveniste E.N. Immune function of astrocytes. Glia. 36:2001;180-190.
61. Soos J.M., Ashley T.A., Morrow J., Patarroyo J.C., Szente B.E., Zamvil S.S. Differential expression of B7 co-stimulatory molecules by astrocytes correlates with T cell activation and cytokine production. Int Immunol. 11:1999;1169-1179.
62. Cornet A., Bettelli E., Oukka M., Cambouris C., Avellana-Adalid V., Kosmatopoulos K., Liblau R.S. Role of astrocytes in antigen presentation and naive T-cell activation. J Neuroimmunol. 106:2000;69-77.
63. Cross A.H., Ku G. Astrocytes and central nervous system endothelial cells do not express B7-1 (CD80) or B7-2 (CD86) immunoreactivity during experimental autoimmune encephalomyelitis. J Neuroimmunol. 110:2000;76-82.
64. Williams K., Alvarez X., Lackner A.A. Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia. 36:2001;156-164.
65. Pratt B.M., McPherson J.M. TGF-[beta] in the central nervous system. potential roles in ischemic injury and neurodegenerative diseases Cytokine Growth Factor Rev. 8:1997;267-292.
66. Letterio J.J., Roberts A.B. TGF-[beta]. a critical modulator of immune cell function Clin Immunol Immunopathol. 84:1997;244-250.
67. Garcion E., Wion-Barbot N., Montero-Menei C.N., Berger F., Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab. 13:2002;100-105.
68. Athanasiou K.A., Niederauer G.G., Agrawal C.M. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials. 17:1996;93-102.
69. Daugherty A.L., Cleland J.L., Duenas E.M., Mrsny R.J. Pharmacological modulation of the tissue response to implanted polylactic-co-glycolic acid microspheres. Eur J Pharm Biopharm. 44:1997;89-102.
70. Lillehei K.O., Kong Q., Withrow S.J., Kleinschmidt-DeMasters B. Efficacy of intralesionally administered cisplatin-impregnated biodegradable polymer for the treatment of 9L gliosarcoma in the rat. Neurosurgery. 39:1996;1191-1197.
71. Newman K.D., Elamanchili P., Kwon G.S., Samuel J. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res. 60:2002;480-486.
72. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
73. Hart D.N. Dendritic cells. unique leukocyte populations which control the primary immune response Blood. 90:1997;3245-3287.
74. Lunsford L., McKeever U., Eckstein V., Hedley M.L. Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle. J Drug Targeting. 8:2000;39-50.
75. Kissel T., Li Y.X., Volland C., Gorich S., Koneberg R. Parenteral protein delivery systems using biodegradable polyesters of ABA block structure, containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethylene oxide) B blocks. J Controlled Release. 39:1996;315-326.
76. Ronneberger B., Kissel T., Anderson J.M. Biocompatibility of ABA triblock copolymer microparticles consisting of poly(-lactic-co-glycolic-acid) A-blocks attached to central poly(oxyethylene) B-blocks in rats after intramuscular injection. Eur J Pharm Biopharm. 43:1997;19-28.
77. Luck M., Pistel K.F., Li Y.X., Blunk T., Muller R.H., Kissel T. Plasma protein adsorption on biodegradable microspheres consisting of poly(D,L-lactide-co-glycolide), poly(L-lactide) or ABA triblock copolymers containing poly(oxyethylene). Influence of production method and polymer composition. J Controlled Release. 55:1998;107-120.
78. Ronneberger B., Kao W.J., Anderson J.M., Kissel T. In vivo biocompatibility study of ABA triblock copolymers consisting of poly(L-lactic-co-glycolic acid) A blocks attached to central poly(oxyethylene) B blocks. J Biomed Mater Res. 30:1996;31-40.
79. Zange R., Li Y., Kissel T. Biocompatibility testing of ABA triblock copolymers consisting of poly(L-lactic-co-glycolic acid) A blocks attached to a central poly(ethylene oxide) B block under in vitro conditions using different L929 mouse fibroblasts cell culture models. J Controlled Release. 56:1998;249-258.
80. Marchant R.E. The cage implant system for determining in vivo biocompatibility of medical device materials. Fund Appl Toxicol. 13:1989;217-227.
81. Dunn RL, English JP, Cowsar DR, Vanderbilt D. Biodegradable in situ forming implants and methods of producing the same. US Patent No. 4,938,763, 1990.
82. Royals M.A., Fujita S.M., Yewey G.L., Rodriguez J., Schultheiss P.C., Dunn R.L. Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. J Biomed Mater Res. 45:1999;231-239.
83. Den Dunnen W.F., Van der Lei B., Robinson P.H., Holwerda A., Pennings A.J., Schakenraad J.M. Biological performance of a degradable poly(lactic acid-epsilon-caprolactone) nerve guide. influence of tube dimensions J Biomed Mater Res. 29:1995;757-766.
84. Den Dunnen W.F.A., Robinson P.H., Van Wessel R., Pennings A.J., Van Leeuwen M.B.M., Schakenraad J.M. Long-term evaluation of degradation and foreign-body reaction of subcutaneously implanted poly(DL-lactide-[epsi]-caprolactone). J Biomed Mater Res. 36:1997;337-346.
85. Streilein J.W., Takeuchi M., Taylor A.W. Immune privilege, T-cell tolerance, and tissue-restricted autoimmunity. Human Immunol. 52:1997;138-143.
86. Barker C.F., Billingham R.E. Immunologically privileged sites. Adv Immunol. 25:1977;1-54.
87. Griffith T.S., Ferguson T.A. The role of FasL-induced apoptosis in immune privilege. Immunol Today. 18:1997;240-244.
88. Streilein J.W., Ksander B.R., Taylor A.W. Immune deviation in relation to ocular immune privilege. J Immunol. 158:1997;3557-3560.
89. Hong S., Van Kaer L. Immune privilege. keeping an eye on natural killer T cells J Exp Med. 190:1999;1197-1200.
90. Peyman G.A., Ganiban G.J. Delivery systems for intraocular routes. Adv Drug Delivery Rev. 16:1995;107-123.
91. Zimmer A., Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Delivery Rev. 16:1995;61-73.
92. Merkli A., Tabatabay C., Gurny R., Heller J. Biodegradable polymers for the controlled release of ocular drugs. Prog Polym Sci. 23:1998;563-580.
93. Yasukawa T., Kimura H., Tabata Y., Ogura Y. Biodegradable scleral plugs for vitreoretinal drug delivery. Adv Drug Delivery Rev. 52:2001;25-36.
94. Hashizoe M., Ogura Y., Takanashi T., Kunou N., Honda Y., Ikada Y. Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. Curr Eye Res. 16:1997;633-639.
95. Miyamoto H., Ogura Y., Hashizoe M., Kunou N., Honda Y., Ikada Y. Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr Eye Res. 16:1997;930-935.
96. Dittgen M., Durrani M., Lehmann K. Acrylic polymers. a review of pharmaceutical applications STP Pharm Sci. 7:1997;403-437.
97. Peppas N.A., Bures P., Leobandung W., Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm. 50:2000;27-46.
98. Kruft M.A., van der Veen F.H., Koole L.H. In vivo tissue compatibility of two radio-opaque polymeric biomaterials. Biomaterials. 18:1997;31-36.
99. Koole L.H., Kruft M-.A.B., Aldenhoff Y.B.J., Van't Oost N.E., Van Kroonenburgh M.J.P.G., Van der Veen F.H. Sustained local drug delivery from a radiopaque implanted reservoir. Nat Biotechnol. 16:1998;172-176.
100. Rihova B., Srogl J., Jelinkova M., Hovorka O., Buresova M., Subr V., Ulbrich K. HPMA-based biodegradable hydrogels containing different forms of doxorubicin. Antitumor effects and biocompatibility. Ann N Y Acad Sci. 831:1997;57-71.
101. Babensee J.E., Cornelius R.M., Brash J.L., Sefton M.V. Immunoblot analysis of proteins associated with HEMA-MMA microcapsules. human serum proteins in vitro and rat proteins following implantation Biomaterials. 19:1998;839-849.
102. Sefton M.V., May M.H., Lahooti S., Babensee J.E. Making microencapsulation work. conformal coating, immobilization gels and in vivo performance J Controlled Release. 65:2000;173-186.
103. Hanes J., Chiba M., Langer R. Degradation of porous poly(anhydride-co-imide) microspheres and implications for controlled macromolecule delivery. Biomaterials. 19:1998;163-172.
104. Laurencin C.T., Ibim S., Uhrich K., Langer R., Bronson R., El-Amin S. The biocompatibility of poly(anhydride-co-imides). high strength polymers for controlled drug delivery Proc Controlled Release Soc. 1997;973-974.
105. Ibim S.M., Uhrich K.E., Bronson R., El-Amin S.F., Langer R.S., Laurencin C.T. Poly(anhydride-co-imides). in vivo biocompatibility in a rat model Biomaterials. 19:1998;941-951.
106. Teomim D., Nyska A., Domb A.J. Ricinoleic acid-based biopolymers. J Biomed Mater Res. 45:1999;258-267.
107. Edlund U., Albertsson A.C. Copolymerisation and polymer blending of trimethylene carbonate and adipic anhydride for tailored drug delivery. J Appl Polym Sci. 72:1999;227-239.
108. Edlund U., Albertsson A.C., Singh S.K., Fogelberg I., Lundgren B.O. Sterilization, storage stability and in vivo biocompatibility of poly(trimethylene carbonate)/poly(adipic anhydride) blends. Biomaterials. 21:2000;945-955.
109. Heller J., Barr J., Ng S.Y., Shen H.R., Schwach-Abdellaoui K., Emmahl S., Rothen-Weinhold A., Gurny R. Poly(ortho esters) - their development and some recent applications. Eur J Pharm Biopharm. 50:2000;121-128.
110. Zignani M., Merkli A., Sintzel M.B., Bernatchez S.F., Kloeti W., Heller J., Tabatabay C., Gurny R. New generation of poly(ortho esters). synthesis, characterization, kinetics, sterilization and biocompatibility J Controlled Release. 48:1997;115-129.
111. Einmahl S., Capancioni S., Schwach-Abdellaoui K., Moeller M., Behar-Cohen F., Gurny R. Therapeutic applications of viscous and injectable poly(ortho esters). Adv Drug Delivery Rev. 53:2001;45-73.
112. Ng S.Y., Shen H.R., Lopez E., Zherebin Y., Barr J., Schacht E., Heller J. Development of a poly(ortho ester) prototype with a latent acid in the polymer backbone for 5-fluorouracil delivery. J Controlled Release. 65:2000;367-374.
113. Zignani M., Bernatchez S.F., Le Minh T., Tabatabay C., Anderson J.M., Gurny R. Subconjunctival biocompatibility of a viscous bioerodable poly(ortho ester). J Biomed Mater Res. 39:1998;277-285.
114. Zignani M., Le Minh T., Einmahl S., Tabatabay C., Heller J., Anderson J.M., Gurny R. Improved biocompatibility of a viscous bioerodible poly(ortho ester) by controlling the environmental pH during degradation. Biomaterials. 21:2000;1773-1778.
115. Zignani M., Einmahl S., Baeyens V., Varesio E., Veuthey J.L., Anderson J., Heller J., Tabatabay C., Gurny R. A poly(ortho ester) designed for combined ocular delivery of dexamethasone sodium phosphate and 5-fluorouracil. subconjunctival tolerance and in vitro release Eur J Pharm Biopharm. 50:2000;251-255.
116. Einmahl S., Behar-Cohen F., Tabatabay C., Savoldelli M., D'Hermies F., Chauvaud D., Heller J., Gurny R. A viscous bioerodible poly(ortho ester) as a new biomaterial for intraocular application. J Biomed Mater Res. 50:2000;566-573.
117. Einmahl S., Savoldelli M., D'Hermies F., Tabatabay C., Gurny R., Behar-Cohen F. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest Ophthalmol Vis Sci. 43:2002;1533-1539.
118. Langone F., Lora S., Veronese F.M., Caliceti P., Parnigotto P.P., Valenti F., Palma G. Peripheral nerve repair using a poly(organo)phosphazene tubular prosthesis. Biomaterials. 16:1995;347-353.
119. Aldini N.N., Fini M., Rocca M., Martini L., Giardino R., Caliceti P., Veronese F.M., Lora S., Maltarello M.C. Peripheral nerve reconstruction with bioabsorbable polyphosphazene conduits. J Bioactive Compatible Polym. 12:1997;3-13.
120. Caliceti P., Aldini N.N., Fini M., Rocca M., Gnudi S., Lora S., Giavaresi G., Monfardini C., Giardino R. Veronese. Bioabsorbable polyphosphazene matrices as systems for calcitonin controlled release. Farmaco. 52:1997;697-702.
121. Aldini N.N., Caliceti P., Lora S., Fini M., Giavaresi G., Rocca M., Torricelli P., Giardino R., Veronese F.M. Calcitonin release system in the treatment of experimental osteoporosis. Histomorphometric evaluation. J Controlled Release. 19:2001;955-961.
122. Shastri P.V. Toxicology of polymers for implant contraceptives for women. Contraception. 65:2002;9-13.
123. Saini P., Greenspan P., Lu D.R. Adsorption of brain proteins on the surface of poly (D,L-lactide-co-glycolide) (PLGA) microspheres. Drug Delivery. 4:1997;129-134.
124. Tzeng J.J., Barth R.F., Orosz C.G., James S.M. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res. 51:1991;2373-2378.
125. Dix A.R., Brooks W.H., Roszman T.L., Morford L.A. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol. 100:1999;216-232.
126. Proescholdt M.A., Merrill M.J., Ikejiri B., Walbridge S., Akbasak A., Jacobson S., Oldfield E.H. Site-specific immune response to implanted gliomas. J Neurosurg. 95:2001;1012-1019.
127. Chen W., He J., Olson J.J., Lu D.R. Carboplatin-loaded PLGA microspheres for intracerebral implantation. in vivo characterization Drug Delivery. 4:1997;301-311.
128. Chen W., He J., Olson J.J., Lu D.R. Direct intracerebral delivery of carboplatin from PLGA microspheres against experimental malignant glioma in rats. Drug Delivery. 5:1998;101-110.
129. Kou J.H., Emmett C., Shen P., Aswani S., Iwamoto T., Vaghefi F., Cain G., Sanders L. Bioerosion and biocompatibility of poly(D,L-lactic-co-glycolic acid) implants in brain. J Controlled Release. 43:1997;123-130.
130. Stensaas S.S., Stensaas L.J. Histopathological evaluation of materials implanted in the cerebral cortex. Acta Neuropathol. 41:1978;145-155.
131. Emerich D.F., Tracy M.A., Ward K.L., Figueiredo M., Qian R., Henschel C., Bartus R.T. Biocompatibility of poly (DL-lactide-co-glycolide) microspheres implanted into the brain. Cell Transplant. 8:1999;47-58.
132. Menei P., Daniel V., Montero-Menei C., Brouillard M., Pouplard-Barthelaix A., Benoit J.P. Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres. Biomaterials. 14:1993;470-478.
133. Menei P., Chirol J.M., Croue A., Cruaud O., Denizot B., Benoit J.P. Distribution and tolerance of biodegradable PLAGA microspheres implanted in the rabbit lumbar subarachnoid space. Proc Controlled Release Soc. 1998;40-41.
134. Veziers J., Lesourd M., Jollivet C., Montero-Menei C., Benoit J.P., Menei P. Analysis of brain biocompatibility of drug-releasing biodegradable microspheres by scanning and transmission electron microscopy. J Neurosurg. 95:2001;489-494.
135. Pean J.M., Menei P., Morel O., Montero-Menei C.N., Benoit J.P. Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons. Biomaterials. 21:2000;2097-2101.
136. Menei P., Pean J.M., Nerriere-Daguin V., Jollivet C., Brachet P., Benoit J.P. Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage. Exp Neurol. 161:2000;259-272.
137. Nicholas A.P., McInnis C., Gupta K.B., Snow W.W., Love D.F., Mason D.W., Ferrell T.M., Staas J.K., Tice T.R. The fate of biodegradable microspheres injected into rat brain. Neurosci Lett. 323:2002;85-88.
138. Utudag H., Horvath V., Black J.P., Sefton M.V. Viability and protein secretion from human hepatoma (HepG2) cells encapsulated in 408. μm polyacrylate microcapsules by submerged nozzle-liquid jet extrusion Biotechnol Bioeng. 44:1994;1199-1204.
139. 3H]PK11195 as a marker for gliosis Biomaterials. 19:1998;829-837.
140. Yoshida H., Date I., Shingo T., Fujiwara K., Miyoshi Y., Furuta T., Ohmoto T. Evaluation of reaction of primate brain to grafted PC12 cells. Cell Transplant. 8:1999;427-430.
141. Mokry J., Karbanova J., Lukas J., Paleckova V., Dvorankova B. Biocompatibility of HEMA copolymers designed for treatment of CNS diseases with polymer-encapsulated cells. Biotechnol Progr. 16:2000;897-904.
142. Lukas J., Smetana K., Petrovicky P., Paleckova V., Vacik J., Dvorankova B., Broz L., Pospisilova D., Holikova Z., Bartuonkova J. Biological properties of copolymer of 2-hydroxyethyl methacrylate with sulfopropyl methacrylate. J Mater Sci: Mater Med. 12:2001;639-646.
143. Smetana K., Vacik J. Anionic polymers for implantation. Ann N Y Acad Sci. 831:1997;95-100.
144. Jirouskova M., Bartunkova J., Smetana K., Lukas J., Vacik J., Dyr J.E. Comparative study of human monocyte and platelet adhesion to hydrogels in vitro - effect of polymer structure. J Mater Sci: Mater Med. 8:1997;19-23.
145. Brem H., Kader A., Epstein J.I., Tamargo R.J., Domb A., Langer R., Leong K.W. Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. Select Cancer Therapy. 5:1989;55-65.
146. Tamargo R.J., Epstein J.I., Reinhard C.S., Chasin M., Brem H. Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res. 23:1989;253-266.
147. Brem H., Domb A., Lenartz D., Dureza C., Olivi A., Epstein J.I. Brain biocompatibility of a biodegradable controlled release polymer consisting of anhydride copolymer of fatty acid dimer and sebacic acid. J Controlled Release. 19:1992;325-329.
148. Olivi A., Kim K.D., Benedetti L., Epstein J.I., Pinn M.L., Callegaro L., Brem H. Ocular and brain biocompatibility of polymeric delivery materials prepared from ester derivatives of hyaluronic acid. Clin Mater. 13:1993;163-168.
149. Brem H., Tamargo R.J., Olivi A., Pinn M., Weingart J.D., Wharam M., Epstein J.I. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg. 80:1994;283-290.
150. Miyoshi Y., Date I., Ohmoto T., Iwata H. Histological analysis of microencapsulated dopamine-secreting cells in agarose/poly(styrene sulfonic acid) mixed gel xenotransplanted into the brain. Exp Neurol. 138:1996;169-175.